الفهرس 
Introduction and Aim of the workOnly 14 pages are availabe for public view
 |  | from | 179 |  |  |
| | | from | 179 | | |
Abstract
Background/Aim: Acute or chronic hepatitis B is an infectious disease that damages the liver. Even though the Hepatitis B vaccine is available, Hepatitis B virus infection remains wide spreading throughout the world and is a substantial cause of illness and mortality. Egypt has an intermediate level of endemicity for the hepatitis B virus (2–8%).The purpose of this study is to assess the effectiveness and safety of Tenofovir Disproxil Fumarate therapy in hepatitis B Egyptian patients as well as the risk of renal impairment in those who have had treatment for hepatitis B.
Methods: This study included 71 chronic hepatitis B patients (aged 21- 69) and age-matched 71 healthy individuals from Mallawi General Hospital-Minia, Egypt, enrolled to the hospital between March and June 2020. Different classical markers were evaluated for all patients and controls. By using sandwich enzyme linked immunosorbent assay, Serum HBsAg levels were determined. Statistical analyses were performed using SPSS program. We collected samples from all patients three months before treatment and three months after treatment.
Result: The levels of Bilirubin (Direct Bilirubin (D. Bil ) and Total Bilirubin (T. Bil )) , Prothrombin Concentration (PC), Platelet count (PLT) and White Blood Cells (WBCs) were significantly decreased in pre-treatment group compared to control group . Phosphorus (PO4), Albumin (ALB), S. Creatinine, the values of the functional liver enzymes (AST and ALT), International Ratio (INR) and Prothrombin Time (PT) were significantly decreased in post treatment when compared to pre-treatment patients group. The levels of Ferritin, ALB, S. Creatinine, PO4, INR, PT, AST and ALT were significantly increased in pre-treatment group compared to control group. Similarly, Ferritin, PC, WBCs and Hemoglobin (Hb%) were significantly increased in post
treatment when compared to pre-treatment patients group. No significant alternations were observed in Alfa Feto Protein (AFP), Random Blood Glucose (RBG) and Hb % in pre-treatment when compared with control group and AFP, RBG, T.Bil , D.Bil and PLT show non-significant alternations in post treatment when compared to pre-treatment patients group.
Conclusion: In summary, even in patients with relatively mild or moderate liver disease at baseline, we demonstrate clear benefits of Tenofovir Disproxil Fumarate (TDF) therapy in an ethnically varied hepatitis B group.